Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorRIDKER, Paul M.-
dc.contributor.authorROSE, Lynda M.-
dc.contributor.authorKASTELEIN, John J. P.-
dc.contributor.authorSANTOS, Raul D.-
dc.contributor.authorWEI, Caimiao-
dc.contributor.authorREVKIN, James-
dc.contributor.authorYUNIS, Carla-
dc.contributor.authorTARDIF, Jean-Claude-
dc.contributor.authorSHEAR, Charles L.-
dc.identifier.citationJOURNAL OF CLINICAL LIPIDOLOGY, v.12, n.4, p.958-965, 2018-
dc.description.abstractBACKGROUND: Familial hypercholesterolemia (FH) is a dominant genetic disorder associated with elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic events. Although therapeutic monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) are indicated for LDL-C reduction among adult patients with FH, placebo-controlled outcome data among FH patients are scant. OBJECTIVE: Directly compare the efficacy of PCSK9 inhibition as compared to placebo on hard cardiovascular outcomes in FH patients enrolled in the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) program. METHODS: We estimated the efficacy of PCSK9 inhibition with bococizumab on future cardiovascular event rates among 1578 FH patients and 15,959 patients without FH who were selected for comparable lipid levels (on-statin levels of LDL-C > 100 mg/dL or non high-density lipoprotein cholesterol > 130 mg/dL). All patients were randomized by computer generated codes to bococizumab 150 mg subcutaneously every 2 weeks or to matching placebo in the SPIRE clinical trials program and were followed over a median period of 11.2 months for major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death). Analysis is by intention to treat. The SPIRE trials are closed and registered at NCT01968954, NCT01968967, NCT02100514, NCT01968980, NCT01975376, and NCT01975389. RESULTS: Compared to non-FH patients, FH patients enrolled in the SPIRE trials were on average younger (58 vs 63 years), more likely to be women (42 vs 35%), more likely to be primary prevention patients (42 vs 23%), had higher mean baseline LDL-C levels (151 vs 127 mg/dL), and lower rates of diabetes (25 vs 52%) and hypertension (59 vs 82%). FH and non-FH patients both had 55% reductions in LDL-C with bococizumab. Among FH patients, major adverse cardiovascular events occurred among 18 of 781 allocated to bococizumab and 22 of 797 allocated to placebo (hazard ratio 0.83; 95% confidence interval 0.44-1.54, P=.55). This best estimate of effect was similar in magnitude to that observed in the much larger group of patients without FH (hazard ratio 0.79, 95% confidence interval 0.64-0.97, P=.023) with no statistically significant evidence of heterogeneity between groups (P=.87). Incidence rate ratios comparing bococizumab to placebo for adverse events were similar among those with and without FH. The proportion of patients developing antidrug antibodies was higher among those with FH compared to those without FH (43% vs 36%, P<.001). CONCLUSIONS: In these randomized placebo-controlled data, the subgroup of statin-treated FH patients had a similar magnitude of risk reduction for hard cardiovascular events with the PCSK9 inhibitor bococizumab as did patients without FH, with no evidence of statistical heterogeneity between groups.-
dc.description.sponsorshipPfizer, New York, NY-
dc.relation.ispartofJournal of Clinical Lipidology-
dc.subjectFamilial hypercholesterolemia-
dc.subjectPCSK9 inhibition-
dc.subjectEvent reduction-
dc.subject.otherdensity-lipoprotein cholesterol-
dc.subject.otherplacebo-controlled trial-
dc.subject.other9 monoclonal-antibody-
dc.subject.otheramg 145-
dc.titleCardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab-
dc.rights.holderCopyright ELSEVIER SCIENCE INC-
dc.contributor.groupauthorStudies PCSK9 Inhibition-
dc.contributor.groupauthorReduction Vasc Events SPIRE Invest-
dc.subject.wosPharmacology & Pharmacy-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, Paul M.:Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA-, Lynda M.:Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA-, John J. P.:Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands-, Caimiao:Pfizer Inc, New York, NY USA-, James:Pfizer Inc, New York, NY USA-, Carla:Pfizer Inc, New York, NY USA-, Jean-Claude:Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada-, Charles L.:CiVi Biopharma, Philadelphia, PA USA-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.relation.referenceBesseling J, 2016, J AM COLL CARDIOL, V68, P252, DOI 10.1016/j.jacc.2016.04.054-
hcfmusp.relation.referenceBesseling J, 2014, ATHEROSCLEROSIS, V233, P219, DOI 10.1016/j.atherosclerosis.2013.12.020-
hcfmusp.relation.referenceCollins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5-
hcfmusp.relation.referencede Ferranti SD, 2016, CIRCULATION, V133, P1067, DOI 10.1161/CIRCULATIONAHA.115.018791-
hcfmusp.relation.referenceGidding SS, 2015, CIRCULATION, V132, P2167, DOI 10.1161/CIR.0000000000000297-
hcfmusp.relation.referenceHuijgen R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009220-
hcfmusp.relation.referenceKastelein JJP, 2017, J CLIN LIPIDOL, V11, P195, DOI 10.1016/j.jacl.2016.12.004-
hcfmusp.relation.referenceKastelein JJP, 2015, EUR HEART J, V36, P2996, DOI 10.1093/eurheartj/ehv370-
hcfmusp.relation.referenceKhera AV, 2016, J AM COLL CARDIOL, V67, P2578, DOI 10.1016/j.jacc.2016.03.520-
hcfmusp.relation.referenceLotta LA, 2016, JAMA-J AM MED ASSOC, V316, P1383, DOI 10.1001/jama.2016.14568-
hcfmusp.relation.referenceNolting PRWD, 2003, J INTERN MED, V253, P161-
hcfmusp.relation.referenceNordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273-
hcfmusp.relation.referenceRaal F, 2012, CIRCULATION, V126, P2408, DOI 10.1161/CIRCULATIONAHA.112.144055-
hcfmusp.relation.referenceRaal FJ, 2017, LANCET DIABETES ENDO, V5, P280, DOI 10.1016/S2213-8587(17)30044-X-
hcfmusp.relation.referenceRaal FJ, 2015, LANCET, V385, P331, DOI 10.1016/S0140-6736(14)61399-4-
hcfmusp.relation.referenceRaal FJ, 2015, LANCET, V385, P341, DOI 10.1016/S0140-6736(14)61374-X-
hcfmusp.relation.referenceRidker PM, 2017, NEW ENGL J MED, V376, P1527, DOI 10.1056/NEJMoa1701488-
hcfmusp.relation.referenceRidker PM, 2017, ANN INTERN MED, V166, P901, DOI 10.7326/M17-0855-
hcfmusp.relation.referenceRidker PM, 2017, NEW ENGL J MED, V376, P1517, DOI 10.1056/NEJMoa1614062-
hcfmusp.relation.referenceRidker PM, 2014, LANCET, V384, P607, DOI 10.1016/S0140-6736(14)61009-6-
hcfmusp.relation.referenceSabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI 10.1056/NEJMoa1615664-
hcfmusp.relation.referenceSeidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699-
hcfmusp.relation.referenceStein EA, 2013, CIRCULATION, V128, P2113, DOI 10.1161/CIRCULATIONAHA.113.004678-
hcfmusp.relation.referenceStein EA, 2012, LANCET, V380, P29, DOI 10.1016/S0140-6736(12)60771-5-
hcfmusp.relation.referenceVallejo-Vaz AJ, 2017, CIRCULATION, V136, P1878, DOI 10.1161/CIRCULATIONAHA.117.027966-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)250.83 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.